{"name":"Mochida Pharmaceutical Company, Ltd.","slug":"mochida-pharmaceutical-company-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Icosapent (MND-2119)","genericName":"Icosapent (MND-2119)","slug":"icosapent-mnd-2119","indication":"Hypertriglyceridemia in patients with elevated cardiovascular risk","status":"phase_3"}]}],"pipeline":[{"name":"Icosapent (MND-2119)","genericName":"Icosapent (MND-2119)","slug":"icosapent-mnd-2119","phase":"phase_3","mechanism":"Icosapent is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism.","indications":["Hypertriglyceridemia in patients with elevated cardiovascular risk"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPdmNLcHJIN3I2aFlfN3BRbHVzYUpiY0E4amhOLU1neWpjaXJvSVBtN3ZHVlFuNDNMdTVMaFBjU2Zuc1BkVmppaXZjM0l4c1lxTllZSTAtZEgxT0g0UGJ4U2UtT2xJQVlFUHk3anl4Y016dzJDWmV0WGNlMThoNXJ6SEhHWWsyQUhtU1pyTXM2RVVJeWVseVlIQUln?oc=5","date":"2026-04-07","type":"pipeline","source":"The Pharma Letter","summary":"Senju and Mochida announce Avarept launch in Japan - The Pharma Letter","headline":"Senju and Mochida announce Avarept launch in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNQWx3QlIycXpBLXdEeTJHTGhkTUM3N0J2cDBDRjJ6TnZjUXBXLV9vOXRlQ25lY081MkxqN1ZSRjNpUHdoZ0lsTWdyeXlWSzREQkNpeUlZX0REbmFWRE4yNXZTbWplSlBHenVpYW9VekhBX0lKYjl4R3d4a1ViVGNxYnBlVGVpWTNxR3lRTGJUVm1mSTBUTG5CcjJQN2ljUFdSeEhrNzkwSG03RUMzRy16YngzVFN0dVRISVhBb1VGQTRYWXpITFEwRlM4S2ZSM1BBc0E?oc=5","date":"2026-03-30","type":"earnings","source":"TipRanks","summary":"Mochida Pharma Clears Audit Review as Profits Rise Ahead of Secondary Share Offering - TipRanks","headline":"Mochida Pharma Clears Audit Review as Profits Rise Ahead of Secondary Share Offering","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxObGlGX0N6N3F4dnF1SmNFblBsNDRIeUcxVXYwQ2ZYTVpDdVNWMUd3V0VTRjdMYk5yRDVhNDZhQzY5Ry1ZV1pPcElBWkJlYUs3VjdTOV9hdVo3ZkVCQ0hzTXZFSlM5dERWY25veE5pdjZZWmJMcXpYVUJLVjRCQXJQbWg2bG5naWwxTmtfMGxjcjd0T21rb1BOTjdWZXdoUENWVXgzM0QxN0p1dWdhVkIxVnp3SXExaFN6dzdJYXEzNTdBZw?oc=5","date":"2026-03-30","type":"pipeline","source":"TipRanks","summary":"Mochida Pharmaceutical Plans Secondary Share Offering to Boost Liquidity - TipRanks","headline":"Mochida Pharmaceutical Plans Secondary Share Offering to Boost Liquidity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQTjc1ZUxSZ3BnZkUyd2JETmpQUm9WbDg5LVFReGdDTV9EbnhfQy1kenBJTWZTQUZjeVpENy1lSVZlVjBYU2loQzRTYkFXUnJDMm9aQVRoWUlnNklWMDFqRWN1WjBzMjA4S2V2blJJZEMwVlhsaDZVWFNEVHFHbHJkLWdOZnNySlhjY0l1Z3lRLWkzTjJtVm1RSHloc21MdXI4WXRIVmxfTmhBUWVZSVZOSGFYRmlvQWRxUkE?oc=5","date":"2026-03-24","type":"pipeline","source":"IPWatchdog.com","summary":"SCOTUS Grants Solicitor General Divided Argument in Hikma Induced Infringement Case - IPWatchdog.com","headline":"SCOTUS Grants Solicitor General Divided Argument in Hikma Induced Infringement Case","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPYTI1eDZRMWlhcUp5Rl9nQ1ZWWENaUXhrVnJHQTAzY3JjRDVUOXQ0SVFRY2d1OTVfUXkxWUdVMTh0TTVvb3RtaU1SVjl3SXBVX0M5dnVzXzllSm5BLW1iWVJ3MkhhdmY2YWw4Tlc4bUhiRTI2dThQV1NWTnZuUkRTaUdDdlhveDN5WGRCRWhLaFlvUUxxRmJiMFA3czVMN09nSWVaWTgwM2V0SHNubXJ2VHFaX2xrUUFTWXNUZTBR?oc=5","date":"2026-03-18","type":"pipeline","source":"AD HOC NEWS","summary":"Mochida Pharmaceutical Stock (ISIN: JP3778400006) Faces Headwinds Amid Japan Pharma Slowdown and Glo - AD HOC NEWS","headline":"Mochida Pharmaceutical Stock (ISIN: JP3778400006) Faces Headwinds Amid Japan Pharma Slowdown and Glo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPUTlxVHpBYVRYaGhER0FnTnEwNjhLUXo2NE9qMkxPRGdKV3BBRFVZLU5Oak43M2o5SGVnUVVtd2V0TmNlOFhzY2xPVTVTNHFwaUZBdDdJRGlvZUlRY2kyb0dMY3pGN0NrRjFpX0YwZmtPWnFDanZoRG9NTnJuZ19oeDVnYkNaUlAwZUtield4SHJYOFlTcElZWXBJVmNORl9GNTBqbGhLbW05WDdXbWFCX1p3WUYwODdGb1p6NndWVWR5bXc?oc=5","date":"2026-03-16","type":"regulatory","source":"AD HOC NEWS","summary":"Mochida Pharmaceutical Stock (ISIN: JP3778400006) Holds Steady Amid Steady Pharma Demand in Japan - AD HOC NEWS","headline":"Mochida Pharmaceutical Stock (ISIN: JP3778400006) Holds Steady Amid Steady Pharma Demand in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNZXVWWXVpU0dGQVdkdXZtMktMNi1YY0xHUUwybnB6c2hFTERZbWVCcnU0aktvbHdwejFEc0ttUjA1YWxmdU9aOG1QTXEwRHRSaGltYVhxNFY2RkIwNEQxa1VLenp2OHJyMEdkTUF0b2tXVHJZS0k2dTRVZHpaMEZkQ1NwVHZyb1V2RlBRSEcyNnZWNTM1M0U5dFFpZTg?oc=5","date":"2026-01-17","type":"regulatory","source":"The Pharma Letter","summary":"Mochida wins new drug approval for Epadel S in China - The Pharma Letter","headline":"Mochida wins new drug approval for Epadel S in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinAJBVV95cUxPbi10ckZEYzJPVmVVamNxY29mZGdpX2xLRXlKYlR4cExhWVQ2dmttUkFnVlI2V3dhRG1ycFpVU0cyNGlrcm9nWmRrempKYW1iNFN1U0M5czROQkFnUHlZMGFXdmlXc3AtZ3RDTXl2QllZYVluNlhtVW9tSEFBSm1oY3g4UzhzdFZYNG1ZN1pTRGpCbVMyVTE4V1V3VFY4aFNHbllVOVhQSFk2Z2tZYThBQUFhR3FSeVViT195b2xQM0RFYkhSMVZvUDZ4NFhaMzhhTDg0Z0R0a1RXS2hsX1g5ak1PUUZjWDlaOENmbm9Od3B6aWNHai1STkVvMnVFY09KRXlUamZtTUNsMlJ4OGMwSU9oWnFVSVRCVUFHbQ?oc=5","date":"2025-12-15","type":"deal","source":"Newswire Canada","summary":"Driven by a common vision, Mochida Pharmaceutical Co., Ltd. and Duchesnay Inc. sign a partnership to help address the issue of drug gap in Japan - Newswire Canada","headline":"Driven by a common vision, Mochida Pharmaceutical Co., Ltd. and Duchesnay Inc. sign a partnership to help address the is","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE91RExBQnVGSGI4OTRWUjJUR0hib1Niek9MSkxsdUJtSjl2d09XNEVPU0VaTVJxVWg3WDlVSXJuQVlKTnpocmtXNUhpLUt6QXpxNVMzY0J5SWdxa1pmVW9sejNLcw?oc=5","date":"2025-10-16","type":"pipeline","source":"Wiley Online Library","summary":"Clinical obesity and Himan-sho (obesity disease): Lessons from Japan's 25 years of experience toward a new era of obesity care - Wiley Online Library","headline":"Clinical obesity and Himan-sho (obesity disease): Lessons from Japan's 25 years of experience toward a new era of obesit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5VZ3pBRTdRVHA4SjF4bmR4TXhScWY5V19lU1FjWGs0aWhrZlFnNm9LSnhDazZvMjA5blh2QzlJejB2MXNEcExpY0pFc1FxQks1blZRZ2VwRk0wejdvSC0w?oc=5","date":"2025-09-01","type":"pipeline","source":"Nature","summary":"Efficacy and safety of esaxerenone with and without sodium–glucose cotransporter-2 inhibitor use in hypertensive patients with type 2 diabetes mellitus: a pooled analysis of five clinical studies - Na","headline":"Efficacy and safety of esaxerenone with and without sodium–glucose cotransporter-2 inhibitor use in hypertensive patient","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPem1Jc3FnYUtYcDZpdnNtb2hLQ2VSQVUyc01CLVZiRDhTMWNjU0dGTkxlNHRqQUMxOHdRZ1pmdWZuRS10N1FNMnBqR3RBbFpuNV9OQXF4WTBFcTJBT2hJVjd2ZUx2THNfM2kyUzhuS3FyN0hUX1pVQzhnNlBibFlSUWVKeVJmSTVhRDhJNEhpbHF3TGdPTDRuNVFjZWNfNXNiUFJXY0dteGdNS3M?oc=5","date":"2024-09-24","type":"regulatory","source":"BioSpectrum Asia","summary":"Nxera Pharma receives approval of insomnia drug in Japan - BioSpectrum Asia","headline":"Nxera Pharma receives approval of insomnia drug in Japan","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9NTjRPcGoxcTZGSnFXVm9fN3dnU19vTUxWdkdzRVYwdjdhcVk2SnJZcExpTk1iV1U5S3JFSUtneGFadHlCNnJGUWdlTjN3ZmpYMGxBcjB6MjAxbzNX?oc=5","date":"2018-11-29","type":"pipeline","source":"Eisai","summary":"MOVICOL® Launched in Japan - Eisai","headline":"MOVICOL® Launched in Japan","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":4,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}